Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cholinergic presynaptic terminal receptor refers to a functional group of receptors located on the presynaptic membranes of cholinergic neurons that modulate the release of acetylcholine (ACh). This group primarily includes muscarinic autoreceptors, specifically the M2 and M4 subtypes, which provide negative feedback to inhibit further neurotransmitter release via G protein-coupled signaling (UniProt P08172, P08173). Additionally, nicotinic autoreceptors, such as the alpha-7 and alpha-4-beta-2 subtypes, are present and often facilitate ACh release through ionotropic mechanisms (PubMed: 10674688). The terminal also expresses various heteroreceptors for other neurotransmitters, such as glutamate or GABA, which further fine-tune acetylcholine output. These receptors are essential for maintaining cholinergic homeostasis and are involved in cognitive processes, memory, and motor control (StatPearls: Physiology, Cholinergic Receptors). Dysregulation of these receptors is associated with neurodegenerative diseases like Alzheimer's and psychiatric conditions like schizophrenia. Pharmacological targeting of these receptors is a strategy used to enhance cholinergic tone or modulate neurotransmitter imbalance, though achieving subtype specificity remains a significant therapeutic challenge (PubMed: 15556490).
Modulation of acetylcholine release through the activation or inhibition of presynaptic autoreceptors (M2, M4, nAChRs) and heteroreceptors.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholinergic presynaptic terminal receptor.